Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
CPOINT Capital Corp is a venture capital firm founded in 2010 and headquartered in Toronto, Canada. The firm focuses on investing in healthcare and pharmaceutical companies that demonstrate sustainable competitive advantages. CPOINT Capital aims to support its portfolio companies through both financial and operational assistance, leveraging its team's extensive experience in the healthcare sector.
Since its inception, CPOINT Capital has established itself as a key player in the healthcare investment landscape, operating globally across North America, Europe, and Asia. The firm has a diverse portfolio that includes companies in various healthcare niches, such as medical devices, diagnostics, and genomics. CPOINT Capital's commitment to its portfolio is evident in its approach to providing not just capital, but also strategic operational support to help companies navigate the complexities of the healthcare market.
As of now, CPOINT Capital manages a portfolio of eight companies, with a focus on high-potential niche markets. The firm has achieved notable milestones, including successful exits from companies like Aspire Pharma and Juno Australia, which highlight its ability to identify and nurture promising healthcare ventures.
CPOINT Capital invests primarily in high-potential niche companies within the healthcare and pharmaceutical sectors. The firm provides both seed and growth capital, emphasizing partnerships with leaders who possess a mix of talent, experience, integrity, passion, and creativity. CPOINT Capital's investment strategy is centered around identifying companies that demonstrate sustainable competitive advantages, particularly in specialty pharmaceuticals, medical devices, diagnostics, and genomics.
The firm operates globally, with a geographic focus that spans North America, Europe, and Asia. CPOINT Capital's investment thesis highlights the importance of operational and commercial support, which it provides to portfolio companies to enhance their chances of success. The firm is particularly interested in companies that require assistance with commercialization, licensing, M&A, distribution, and regulatory navigation.
Check sizes are not publicly disclosed, but CPOINT Capital has demonstrated a willingness to invest significant amounts in its portfolio companies, as evidenced by a recent follow-on investment totaling $750,000 in Conavi Medical. This indicates a proactive approach to supporting its investments through various stages of growth.
CPOINT Capital's portfolio consists of eight companies, each focused on innovative solutions within the healthcare sector. The following are key portfolio companies:
Ian Jacobson - Founder and Partner. Ian has over 43 years of experience in the pharmaceutical industry. Before founding CPOINT Capital and Juno Pharmaceuticals in 2010, he served as CEO of Cobalt Pharmaceuticals and held senior roles at Genpharm Canada, Amerpharm/Merck KGaA, and Par Pharmaceuticals.
Craig Podolsky - Founder and Partner. Craig is a founding partner at CPOINT and the founder/president of the Juno Group of Companies. He focuses on seeding, investing in, and acquiring healthcare companies, particularly in the generic and specialty pharmaceuticals and medical devices sectors.
Allan Mandelzys, PhD, MBA - Chief Operating Officer and Chief Development Officer. Allan joined CPOINT as a partner in 2022 and also serves as COO/CDO for Juno Pharmaceuticals. His background includes roles in biotech, specialty and generic pharma, and business development across various companies.
Chris Ichiyen, CPA, CA - VP Finance. Chris is a finance executive with experience in the healthcare and pharmaceutical sectors, including roles at Cobalt/Watson/Actavis and KPMG. He has expertise in M&A and post-acquisition integration across large pharmaceutical transactions.
To pitch CPOINT Capital, founders should visit their website at cpointcapital.com. It is recommended to include a comprehensive business plan in the pitch deck, detailing the startup's unique value proposition, market analysis, and team qualifications. Founders should also highlight any traction or milestones achieved to date.
While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's focus on healthcare investments. Warm introductions may enhance the chances of securing a meeting, as CPOINT Capital values connections within the industry.
In April 2025, CPOINT Capital announced a follow-on investment in Conavi Medical, totaling $750,000 as part of a public offering. This investment highlights the firm's ongoing commitment to supporting its portfolio companies through various stages of growth.
In 2023, CPOINT Capital exited its investment in Juno Australia, a distributor of injectable generics and biosimilars, to Arrotex. This exit demonstrates the firm's ability to identify and capitalize on successful investment opportunities within the healthcare sector.
Additionally, CPOINT Capital sold a majority position in Aspire Pharma to H.I.G. Capital in 2021 while retaining a minority stake, showcasing its successful track record in the specialty pharmaceutical market.
What are CPOINT Capital's investment criteria?
CPOINT Capital focuses on high-potential niche companies within the healthcare and pharmaceutical sectors. The firm seeks companies that demonstrate sustainable competitive advantages and are led by individuals with the right mix of talent, experience, integrity, passion, and creativity.
How can founders pitch to CPOINT Capital?
Founders can pitch to CPOINT Capital through their website at cpointcapital.com. It is advisable to include a detailed business plan that outlines the company's unique value proposition, market potential, and the team’s qualifications.
What makes CPOINT Capital different from other investors?
CPOINT Capital differentiates itself by providing not only capital but also operational and commercial support to its portfolio companies. The firm's team has extensive experience in the healthcare and pharmaceutical sectors, allowing them to assist with commercialization, licensing, M&A, and regulatory navigation.
What is CPOINT Capital's geographic scope?
The firm operates globally, with investments across North America, Europe, and Asia. This broad geographic reach allows CPOINT Capital to tap into diverse markets and opportunities within the healthcare sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, CPOINT Capital has demonstrated a willingness to invest significant amounts in its portfolio companies, as seen in a recent follow-on investment of $750,000 in Conavi Medical.
What type of support can portfolio companies expect post-investment?
Portfolio companies can expect both financial and operational support from CPOINT Capital. The firm assists with commercialization strategies, regulatory navigation, and market access, leveraging its team's expertise in the healthcare sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.